Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tumor necrosis factor alpha (TNF-α) is a potent proinflammatory cytokine produced by various cell types, notably mononuclear cells such as monocytes and macrophages, as well as T cells, B cells, and natural killer (NK) cells. 'TNF-α-expressing mononuclear cell' typically refers to a peripheral blood or tissue-resident immune cell of the mononuclear lineage that actively produces or expresses TNF-α. These cells play a key role in initiating and amplifying inflammatory responses through the secretion of TNF-α, which promotes recruitment of additional immune effector cells and stimulates production of other proinflammatory mediators. Overproduction or dysregulated expression of TNF-α by these mononuclear populations is implicated in numerous diseases, including autoimmune disorders, chronic inflammatory diseases, and infectious disease responses. Neutralization or inhibition of this pathway forms the basis for several anti-TNF therapies used clinically.
Neutralization or inhibition of TNF-α signaling pathway
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tumor Necrosis Factor Alpha-Expressing Mononuclear Cell.